EGFR and non-small cell lung carcinoma: This observation agrees with the findings by Raoof et al. reporting upregulation of multiple FGF ligands, including FGF1, in the drug tolerant mechanisms arising in NSCLC cells treated with EGFR TKI for two weeks [28].